Human papillomavirus load in Hybrid Capture II assay: Does increasing the cutoff improve the test?

Gynecologic Oncology

Volumn 99, Issue 2, 2005, Pages 313-319

  Ordi, Jaume ^a   Alonso, Imma ^a   Torné, Aureli ^a   Esteve, Roser ^a   Sierra, Erika ^a   Campo, Elias ^a   Puig Tintoré, Luis M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus; Hybrid capture; Viral load

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CLINICAL TRIAL; COLPOSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; FEMALE; HUMAN; HYBRID; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PREDICTION; PRIORITY JOURNAL; PROBABILITY; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VIRUS DETECTION; VIRUS LOAD; WART VIRUS;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; FEMALE; HUMANS; MIDDLE AGED; NUCLEIC ACID HYBRIDIZATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; VIRAL LOAD;

EID: 27144499018     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.07.011     Document Type: Article

References (35)

1. F.X. Bosch, A. Lorincz, N. Muñoz, C.J. Meijer, and K.V. Shah The causal relation between human papillomavirus and cervical cancer J. Clin. Pathol. 55 2002 244 265
2. J.M. Walboomers, M.V. Jacobs, M.M. Manos, F.X. Bosch, J.A. Kummer, and K.V. Shah Human papillomavirus is a necessary cause of invasive cervical cancer worldwide J. Pathol. 189 1999 12 19
3. C. Clavel, M. Masure, J.P. Bory, I. Putaud, C. Mangeonjean, and M. Lorenzato Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women Br. J. Cancer 84 2001 1616 1623
4. C. Clavel, J. Cucherousset, M. Lorenzato, S. Caudroy, J.M. Nou, and P. Nazeyrollas Negative human papillomavirus testing in normal smears selects a population at low risk for developing high-grade cervical lesions Br. J. Cancer 90 2004 1803 1808
5. M.A. Nobbenhuis, J.M. Walboomers, T.J. Helmerhorst, L. Rozendaal, A.J. Remmink, and E.K. Risse Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study Lancet 354 1999 20 25
6. J. Ordi, L.M. Puig-Tintore, A. Torne, S. Sanz, R. Esteve, and C. Romagosa Contribution of high risk human papillomavirus testing to the management of premalignant and malignant lesions of the uterine cervix Med. Clin. (Barc) 121 2003 441 445
7. G.D. Zielinski, P.J. Snijders, L. Rozendaal, F.J. Voorhorst, H.C. van der Linden, and A.P. Runsink HPV presence precedes abnormal cytology in women developing cervical cancer and signals false negative smears Br. J. Cancer 85 2001 398 404
8. M.M. Manos, W.K. Kinney, L.B. Hurley, M.E. Sherman, J. Shieh-Ngai, and R.J. Kurman Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results JAMA 281 1999 1605 1610
9. D. Riethmuller, C. Gay, X. Bertrand, D. Bettinger, J.P. Schaal, and J.P. Carbillet Genital human papillomavirus infection among women recruited for routine cervical cancer screening or for colposcopy determined by Hybrid Capture II and polymerase chain reaction Diagn. Mol. Pathol. 8 1999 157 164
10. J. Cuzick, E. Beverley, L. Ho, G. Terry, H. Sapper, and I. Mielzynska HPV testing in primary screening of older women Br. J. Cancer 81 1999 554 558
11. M. Howard, J. Sellors, and J. Kaczorowski Optimizing the Hybrid Capture II human papillomavirus test to detect cervical intraepithelial neoplasia Obstet. Gynecol. 100 2002 972 980
12. S.M. Kulmala, S. Syrjanen, I. Shabalova, N. Petrovichev, V. Kozachenko, and J. Podistov Human papillomavirus testing with the hybrid capture 2 assay and PCR as screening tools J. Clin. Microbiol. 42 2004 2470 2475
13. H.P. Lin, Y.Y. Huang, H.Y. Wu, and J.T. Kao Method for testing for human papillomavirus infection in patients with cervical intraepithelial disease J. Clin. Microbiol. 42 2004 366 368
14. National Cancer Institute Workshop The 1988 Bethesda System for reporting cervical/vaginal cytological diagnoses JAMA 262 1989 931 934
15. D. Solomon, D. Davey, R. Kurman, A. Moriarty, D. O'Connor, M. Prey Forum Group Members; Bethesda 2001 Workshop The 2001 Bethesda system: terminology for reporting results of cervical cytology JAMA 124 2001 2114 2119
16. International colposcopic terminology A. Singer J.M. Monaghan Lower genital tract precancer: colposcopy, pathology and treatment 1994 Blackwell Scientific Publications 47 110
17. C.E. Metz, B.A. Herman, and J.H. Shen Maximum likelihood estimation of receiver operating characteristic (ROC) curves from continuously-distributed data Stat. Med. 17 1998 1033 1053
18. V. Dalstein, D. Riethmuller, J.L. Sautiere, J.L. Pretet, B. Kantelip, and J.P. Schaal Detection of cervical precancer and cancer in a hospital population; benefits of testing for human papillomavirus Eur. J. Cancer 40 2004 1225 1232
19. J. Cuzick, A. Szarewski, H. Cubie, G. Hulman, H. Kitchener, and D. Luesley Management of women who test positive for high-risk types of human papillomavirus: the HART study Lancet 362 2003 1871 1876
20. G.Y. Ho, R. Bierman, L. Beardsley, C.J. Chang, and R.D. Burk Natural history of cervicovaginal papillomavirus infection in young women N. Engl. J. Med. 338 1998 423 428
21. E.L. Franco, L.L. Villa, J.P. Sobrinho, J.M. Prado, M.C. Rousseau, and M. Desy Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer J. Infect. Dis. 180 1999 1415 1423
22. P.E. Castle, M. Schiffman, R.D. Burk, S. Wacholder, A. Hildesheim, and R. Herrero Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types Cancer Epidemiol., Biomarkers Prev. 11 2002 1394 1399
23. A. Guyot, S. Karim, M.S. Kyi, and J. Fox Evaluation of adjunctive HPV testing by Hybrid Capture II in women with minor cytological abnormalities for the diagnosis of CIN2/3 and cost comparison with colposcopy BMC Infect. Dis. 3 2003 23
24. P. Nieminen, S. Vuorma, M. Viikki, M. Hakama, and A. Anttila Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer BJOG 111 2004 842 848
25. C.L. Peyton, M. Schiffman, A.T. Lorincz, W.C. Hunt, I. Mielzynska, and C. Bratti Comparison of PCR- and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies J. Clin. Microbiol. 36 1998 3248 3254
26. L. Kuhn, L. Denny, A. Pollack, A. Lorincz, R.M. Richart, and T.C. Wright Human papillomavirus DNA testing for cervical cancer screening in low-resource settings J. Natl. Cancer Inst. 92 2000 818 825
27. M. Schiffman, R. Herrero, A. Hildesheim, M.E. Sherman, M. Bratti, and S. Wacholder HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica JAMA 283 2000 87 93
28. P.J.F. Snijders, A.J.C. van den Brule, and C.J.L.M. Meijer The clinical relevance of human papillomavirus testing. Relationship between analytical and clinical sensitivity J. Clin. Pathol. 201 2003 1 6
29. R. Guido, M. Schiffman, D. Solomon, and L. Burke ASCUS LSIL Triage Study (ALTS) Group. Postcolposcopy management strategies for women referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: a two-year prospective study Am. J. Obstet. Gynecol. 188 2003 1401 1405
30. I. Nindl, A. Lorincz, I. Mielzynska, U. Petry, S. Baur, and R. Kirchmayr Human papillomavirus detection in cervical intraepithelial neoplasia by the second-generation hybrid capture microplate test, comparing two different cervical specimen collection methods Clin. Diagn. Virol. 10 1998 49 56
31. A.T. Lorincz, P.E. Castle, M.E. Sherman, D.R. Scott, A.G. Glass, and S. Wacholder Viral load of human papillomavirus and risk of CIN3 or cervical cancer Lancet 360 2002 228 229
32. A.M. Josefsson, P.K. Magnusson, N. Ylitalo, P. Sorensen, P. Qwarforth-Tubbin, and P.K. Andersen Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study Lancet 355 2000 2189 2193
33. N. Ylitalo, P. Sorensen, A.M. Josefsson, P.K. Magnusson, P.K. Andersen, and J. Ponten Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study Lancet 355 2000 2194 2198
34. M. van Duin, P.J. Snijders, H.F. Schrijnemakers, F.J. Voorhorst, L. Rozendaal, and M.A. Nobbenhuis Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance Int. J. Cancer 98 2002 590 595
35. C. Clavel, M. Masure, J.P. Bory, I. Putaud, C. Mangeonjean, and M. Lorenzato Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: a preliminary study on 1518 women Br. J. Cancer 80 1999 1306 1311